Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 166

Sort by

Sort Order Select

Journal Articles

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Blood blood.2024024526.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

Blood (2023) 142 (Supplement 1): 5138.

https://doi.org/10.1182/blood-2023-180241

Published: 2023

Journal Articles

Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression

Benoît Tisserand, Caroline Bret, Yassine Al Tabaa, Sylvain Lamure, Xavier Ayrignac, Laura Platon, Patrice Ceballos, Ludovic Gabellier, Jerome Moreaux, Charles Herbaux, Guillaume Cartron, Jean-Jacques Tudesq

Blood (2023) 142 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2023-185520

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology

Emmanuel Varlet, Elina Alaterre, Morgane Thomas, Hugues De Boussac, Laure Vincent, Guillaume Cartron, Charles Herbaux, Caroline Bret, Laurie Herviou, Anne Marie Martinez, Christophe Hirtz, Aurore Attina, Jerome Vialaret, Giacomo Cavalli, Jerome Moreaux, Sara Ovejero

Blood (2023) 142 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2023-181018

Published: 2023

Journal Articles

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Elvira Garcia De Paco, Caroline Soulet, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Laure Vincent, Charles Herbaux, Maria Moriel-Carretero, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2023-181039

Published: 2023

Journal Articles

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Blood (2023) 142 (Supplement 1): 893.

https://doi.org/10.1182/blood-2023-177703

Published: 2023

Journal Articles

Low Tmtv Influences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry

Yassine Al Tabaa, Clément Bailly, Xavier Pallard, Anne Ségolène Cottereau, Jérémie Tordo, Pierre Sesques, Guillaume Cartron, Roch Houot, Roberta Di Blasi, Salim Kanoun, Caroline Milin, Françoise Kraeber-Bodéré, Laetitia Vercellino

Blood (2023) 142 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2023-185794

Published: 2023

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

Single-Cell Longitudinal Characterization of FL Heterogeneity and Residual Disease in the Bone Marrow from Low-Tumor Burden FL Enrolled in the Flirt Clinical Trial

Alicia Beyou, Simon Leonard, Ilenia Papa, Noushin Mossadegh-Keller, Sabrina Baaklini, Lionel Spinelli, Owen Hoare, Bertrand Nadel, Pierre Milpied, Joelle Dulong, Céline Monvoisin, Gabriel Brisou, Guillaume Cartron, Karin Tarte, Sandrine Roulland

Blood (2023) 142 (Supplement 1): 852.

https://doi.org/10.1182/blood-2023-186070

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2023-186570

Published: 2023

Journal Articles

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Laure Dutrieux, Elle Loughran, Armelle Choquet, Hélène Herault, Antoine Guillemin, Nicolas Robert, Guilhem Requirand, Guillaume Cartron, Laure Vincent, Charles Herbaux, Eric Rivals, Alexandre David, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2023-184749

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Blood (2023) 142 (Supplement 1): 170.

https://doi.org/10.1182/blood-2023-178030

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu

Blood (2023) 142 (Supplement 1): 668.

https://doi.org/10.1182/blood-2023-180175

Published: 2023

Journal Articles

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Loic Ysebaert, Roch Houot, Olivier Casasnovas, Choquet Sylvain, Fabrice Jardin, Michael Loschi, Gabriel Brisou, Catherine Thieblemont, Jacques-Olivier Bay, Cristina Castilla-Llorente, Tom Fradon, Steven Le Gouill, Franck Morschhauser, Guillaume Cartron, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 296.

https://doi.org/10.1182/blood-2023-184653

Published: 2023

Journal Articles

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Julio C. Chavez, Loretta J. Nastoupil, Franck Morschhauser, Guillaume Cartron, Judit Mészáros Joergensen, Emmanuel Bachy, Pierre Bories, Victoria Campbell, Bijou Fontanet, Poliana P. Patah, Bérengère de Moucheron, Soraya Carrancio, Xirong Zheng, Chaoqun Mei, Michael Pourdehnad, Jean-Marie Michot

Blood (2023) 142 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2023-188771

Published: 2023

NARROW

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Low Tmtv Influences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Single-Cell Longitudinal Characterization of FL Heterogeneity and Residual Disease in the Bone Marrow from Low-Tumor Burden FL Enrolled in the Flirt Clinical Trial

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only